Publicaciones en colaboración con investigadores/as de Institut d'Investigació Biomédica de Bellvitge (15)

2019

  1. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

    Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701

  2. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  3. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

    Therapeutic Advances in Medical Oncology, Vol. 11

2017

  1. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

    Stem Cell Reports, Vol. 8, Núm. 5, pp. 1392-1407

2015

  1. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

    Oncotarget, Vol. 6, Núm. 42, pp. 44254-44273

2014

  1. VAV3 mediates resistance to breast cancer endocrine therapy

    Breast Cancer Research, Vol. 16, Núm. 3

2012

  1. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis

    Cancer Research, Vol. 72, Núm. 11, pp. 2879-2888

2011

  1. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines

    Breast Cancer Research, Vol. 13, Núm. 6

  2. Evidence for a link between TNFRSF11A and risk of breast cancer

    Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954

  3. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer

    PLoS Biology, Vol. 9, Núm. 11

2010

  1. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: A prospective analysis of axillary or distant recurrence

    Annals of Surgical Oncology, Vol. 17, Núm. 3, pp. 772-777

  2. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer

    Oncogene, Vol. 29, Núm. 45, pp. 6071-6083

  3. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer

    Annals of the New York Academy of Sciences, Vol. 1210, Núm. 1, pp. 86-92

2009

  1. Biological convergence of cancer signatures

    PLoS ONE, Vol. 4, Núm. 2

2008

  1. Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer

    Breast Cancer Research and Treatment, Vol. 109, Núm. 3, pp. 463-470